The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia
Ben Grayson, Giovanni Podda, Jackie Cilia, Marie Woolley-Roberts, Joanna C. Neill, Jennifer Fletcher, Michael K Harte
Journal of Psychopharmacology March 1, 2026 DOI: 10.1177/02698811251381246 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical animal study Peer reviewed |
|---|---|
| Population | Female Lister Hooded rats treated with sub-chronic phencyclidine (scPCP) or saline |
| Interventions | Cannabidivarin (CBDV) Risperidone Phencyclidine (scPCP) |
| Dose | CBDV 2, 10, and 20 mg/kg, i.p.; risperidone 0.1 mg/kg, i.p.; scPCP 2 mg/kg, i.p. |
| Duration | 7 days of scPCP or saline, followed by a minimum 7-day drug-free washout; treatments given 60 minutes before testing |
| Measures | Novel object recognition (NOR), social interaction (SI), reversal learning (RL) |
| Key points | Sub-chronic phencyclidine impaired novel object recognition, social interaction, and reversal learning in rats. CBDV at 10 and 20 mg/kg improved recognition and social interaction deficits, and 20 mg/kg reversed the reversal-learning deficit; risperidone (0.1 mg/kg) reversed deficits in all three tests. The authors state this is the first demonstration of CBDV ameliorating cognitive and social deficits in this model. |
Abstract
Background: Schizophrenia is a serious psychiatric disorder that affects over 24 million people worldwide. Current therapies treat positive symptoms but show little efficacy for negative and cognitive symptoms, which can impact quality of life. Development of effective medication for this unmet medical need is imperative. Phytocannabinoids, such as cannabidivarin (CBDV), show promising results for the treatment of neurological disorders and have demonstrated efficacy in preclinical models, including seizure, autism, Rett, and Fragile X syndromes.
Aim: To determine the effect of CBDV on cognitive and social deficits in a sub-chronic phencyclidine (scPCP) rat model of relevance to schizophrenia.
Methods: Female Lister Hooded rats received scPCP (2 mg/kg, intraperitoneally (i.p.)) or saline for 7 days, followed by a minimum 7-day drug-free washout. Rats were then treated with saline, CBDV (2, 10, and 20 mg/kg, i.p.), or risperidone (0.1 mg/kg, i.p.) 60 minutes before novel object recognition (NOR), social interaction (SI), and reversal learning (RL) testing.
Results: scPCP significantly impaired performance in all three behavioural tests. Deficits in the NOR and SI tests were significantly improved by CBDV (10 and 20 mg/kg), while 20 mg/kg was effective at reversing the deficits in RL. Risperidone also significantly reversed the scPCP-induced deficit in the NOR, RL, and SI paradigms.
Conclusion: Here, we are the first to demonstrate the ability of CBDV to ameliorate cognitive and social deficits in the scPCP rat model of relevance for schizophrenia, suggesting further research is justified into the potential therapeutic benefits of CBDV in patients.
Citations in the library
Cites 4
- Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age Frontiers in Immunology September 21, 2018
- Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory Journal of Psychopharmacology May 7, 2019
- The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Current Pharmaceutical Design 2014
- Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacology, Biochemistry, and Behavior August 2009